RPCI-UPCI Ovarian Cancer SPORE Clinical Trials

Available Clinical Trials

SPORE Project 1
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen

SPORE Project 4
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer

Cancer Immunotherapy Trials Network
A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Checkpoint Inhibitors
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects With Advanced Solid Tumors

Upcoming Clinical Trials

  • A Phase I/IIa Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination with Decitabine in Patients with Recurrent or Treatment Refractory
  • A Phase I study of MHC-restricted and MHC-non-restricted targeting of ovarian cancer by αDC1-induced CTLs

View a list of all SPOREs provided by the Translational Research Program at the National Cancer Institute.